Cargando…

Beyond chemotherapy for advanced disease—the role of EGFR and PD-1 inhibitors

Penile squamous cell carcinoma (SCC) is a rare malignancy with limited treatment options when the tumor is unresectable and/or chemorefractory. Triplet systemic chemotherapy regimens including taxane and cisplatin are recommended, but the response duration can be short and the treatment-related toxi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Weijie, Zhu, Yao, Ye, Dingwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673798/ https://www.ncbi.nlm.nih.gov/pubmed/29184782 http://dx.doi.org/10.21037/tau.2017.03.92

Ejemplares similares

The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma
por: Xiang, Xiaoyong, et al.
Publicado: (2023)

PD-1 Inhibitors in the Advanced Esophageal Cancer
por: Hong, Ye, et al.
Publicado: (2019)

Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis
por: Guo, Xiaodi, et al.
Publicado: (2020)

PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas
por: Tian, Zhichao, et al.
Publicado: (2022)

Clinical outcome of advanced and metastatic renal cell carcinoma treated with targeted therapy: is there a difference between young and old patients?
por: Zhang, Guiming, et al.
Publicado: (2014)

Prognostic Value of Components of Body Composition in Patients Treated with Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Case Series
por: Gu, Weijie, et al.
Publicado: (2015)

Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
por: Zhu, Chengpei, et al.
Publicado: (2023)

Continuous EGFR tyrosine kinase inhibitor treatment with or without chemotherapy beyond gradual progression in non-small cell lung cancer patients
por: Peng, Ling, et al.
Publicado: (2017)

Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer
por: Zhai, Xiaoyang, et al.
Publicado: (2020)

Pazopanib together with 6–8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma
por: Lu, Xiaolin, et al.
Publicado: (2021)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer
por: Xiao, Weiwei, et al.
Publicado: (2023)

Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Mei, Jie, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitors versus Chemotherapy for Previously Treated Advanced Gastroesophageal Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Maoxi, Zhong, et al.
Publicado: (2021)

PD-1 Inhibitor Plus Chemotherapy Versus Chemotherapy as First-line Treatment for Advanced Esophageal Cancer: A Systematic Review and Meta-Analysis
por: Lu, Yao, et al.
Publicado: (2022)

Efficacy and safety of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitor versus chemotherapy for advanced lung cancer: A meta-analysis
por: Zhang, Pei-Pei, et al.
Publicado: (2021)

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
por: Li, Xiang, et al.
Publicado: (2021)

The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer
por: Sheng, Zhixin, et al.
Publicado: (2017)

PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study
por: Chen, Mifen, et al.
Publicado: (2023)

Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer
por: Yao, W., et al.
Publicado: (2021)

Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
por: Singh, Vishakha, et al.
Publicado: (2021)

Beyond Chemotherapy, PD-1, and HER-2: Novel Targets for Gastric and Esophageal Cancer
por: Siddiqui, Ali Zubair, et al.
Publicado: (2021)

Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages
por: Lu, Di, et al.
Publicado: (2019)

Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma
por: Koh, Young Wha, et al.
Publicado: (2023)

Phase II study of docetaxel, cisplatin, and fluorouracil in patients with distantly metastatic penile cancer as first-line chemotherapy
por: Zhang, Sheng, et al.
Publicado: (2015)

PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors
por: Rosell, Rafael, et al.
Publicado: (2015)

Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of sunitinib
por: Lu, Xiaolin, et al.
Publicado: (2016)

PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis
por: Zhu, Xinxin, et al.
Publicado: (2021)

The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
por: Tang, Yanna, et al.
Publicado: (2015)

Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cancer
por: Zheng, Qitong, et al.
Publicado: (2021)

Efficacy and optimal combination timing of chemotherapy combined with PD-1 inhibitor in advanced cervical cancer: a multicenter retrospective cohort study
por: Ma, Yi-Ming, et al.
Publicado: (2022)

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
por: De Giglio, Andrea, et al.
Publicado: (2021)

PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study
por: Chen, Shubin, et al.
Publicado: (2022)

Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis
por: Liu, Bo-Wei, et al.
Publicado: (2023)

PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib
por: Xu, Yongkang, et al.
Publicado: (2022)

Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study
por: Tian, Zhichao, et al.
Publicado: (2020)

The Combined Use of Chemotherapy and Radiotherapy with PD-1 Inhibitor, Pembrolizumab, in Advanced Cervical Cancer: A Case Report
por: Lyu, Mengmeng, et al.
Publicado: (2020)

Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients
por: Yan, Han, et al.
Publicado: (2015)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors
por: Kou, Wen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_76kc7vu24ehgou9ti91dpteut5